NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
Clinical Trials
6 trialsNCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT03391466 2025-12-01
ZUMA-7
Gilead Sciences
Phase 3 Completed
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT05108805 2025-03-27
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
Phase 4 Completed